Recursion Pharmaceuticals Q3 2026 Results: Net Loss of $119M, Loss Narrows
Recursion Pharmaceuticals reported a net loss of $119.0 million for the third quarter of 2026, an improvement from the $162.3 million loss in the prior year period. Total revenue increased significantly to $18.6 million for the quarter, while the company maintained a strong liquidity position with $549.9 million in cash and cash equivalents as of September 30, 2026.
- Key figure
- Net loss $119M